MA40224B1 - Anticorps se liant aux protofibrilles ass améliorés - Google Patents

Anticorps se liant aux protofibrilles ass améliorés

Info

Publication number
MA40224B1
MA40224B1 MA40224A MA40224A MA40224B1 MA 40224 B1 MA40224 B1 MA 40224B1 MA 40224 A MA40224 A MA 40224A MA 40224 A MA40224 A MA 40224A MA 40224 B1 MA40224 B1 MA 40224B1
Authority
MA
Morocco
Prior art keywords
protofibrils
ass
enhanced
antibodies binding
antibodies
Prior art date
Application number
MA40224A
Other languages
English (en)
Other versions
MA40224A (fr
Inventor
Charlotte Nerelius
Hanna Laudon
Jessica Sigvardson
Original Assignee
Eisai R&D Man Co Ltd
Bioarctic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd, Bioarctic Ab filed Critical Eisai R&D Man Co Ltd
Publication of MA40224A publication Critical patent/MA40224A/fr
Publication of MA40224B1 publication Critical patent/MA40224B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La présente invention concerne le peptide bêta amyloïde (aß) et, plus spécifiquement, des anticorps se liant à des protofibrilles aß et leur utilisation à des fins thérapeutiques et/ou pour le traitement prophylactique de la maladie d'alzheimer et d'autres troubles associés à l'agrégation des protéines aß. En outre, l'invention peut se rapporter au diagnostic de telles maladies, ainsi qu'au suivi de la progression de la maladie grâce à l'utilisation des anticorps de l'invention. En outre, l'invention peut se rapporter à un usage vétérinaire des anticorps de l'invention.
MA40224A 2014-07-10 2015-07-08 Anticorps se liant aux protofibrilles ass améliorés MA40224B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462022952P 2014-07-10 2014-07-10
PCT/EP2015/065633 WO2016005466A2 (fr) 2014-07-10 2015-07-08 Anticorps se liant aux protofibrilles ass améliorés

Publications (2)

Publication Number Publication Date
MA40224A MA40224A (fr) 2017-05-17
MA40224B1 true MA40224B1 (fr) 2021-05-31

Family

ID=53673920

Family Applications (2)

Application Number Title Priority Date Filing Date
MA40224A MA40224B1 (fr) 2014-07-10 2015-07-08 Anticorps se liant aux protofibrilles ass améliorés
MA053887A MA53887A (fr) 2014-07-10 2015-07-08 Anticorps à liaison protofibrille a-bêta améliorée

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA053887A MA53887A (fr) 2014-07-10 2015-07-08 Anticorps à liaison protofibrille a-bêta améliorée

Country Status (32)

Country Link
US (1) US9573994B2 (fr)
EP (2) EP3166970B1 (fr)
JP (1) JP6628786B2 (fr)
KR (2) KR102564384B1 (fr)
CN (2) CN106661103B (fr)
AR (1) AR101130A1 (fr)
AU (1) AU2015286707B2 (fr)
CA (1) CA2951990C (fr)
CL (1) CL2017000053A1 (fr)
CO (1) CO2017000346A2 (fr)
CY (1) CY1124563T1 (fr)
DK (1) DK3166970T3 (fr)
ES (1) ES2865112T3 (fr)
HR (1) HRP20210680T1 (fr)
HU (1) HUE053809T2 (fr)
IL (2) IL282823B2 (fr)
JO (1) JO3537B1 (fr)
LT (1) LT3166970T (fr)
MA (2) MA40224B1 (fr)
MX (1) MX2017000378A (fr)
MY (1) MY184890A (fr)
PE (1) PE20170768A1 (fr)
PH (1) PH12017500032A1 (fr)
PL (1) PL3166970T3 (fr)
PT (1) PT3166970T (fr)
RS (1) RS61717B1 (fr)
RU (1) RU2700104C2 (fr)
SG (1) SG11201610734RA (fr)
SI (1) SI3166970T1 (fr)
TW (1) TWI678376B (fr)
WO (1) WO2016005466A2 (fr)
ZA (1) ZA201706272B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11327080B2 (en) 2015-07-21 2022-05-10 BioArctic Neruoscience AB Method for treatment of traumatic brain injury targeting aggregated peptides
JP2019529345A (ja) 2016-07-14 2019-10-17 バイオアークティック アクティエボラーグ 脳送達タンパク質
CN117244056A (zh) * 2016-10-27 2023-12-19 卫材研究发展管理有限公司 用于治疗阿尔茨海默病的含有抗Aβ初原纤维抗体和β-分泌酶BACE1抑制剂的组合物
JP7398380B2 (ja) * 2018-03-08 2023-12-14 フェインズ セラピューティクス，インコーポレーテッド 抗クローディン１８．２抗体及びその使用
CN112805031A (zh) 2018-07-24 2021-05-14 卫材R&D管理有限公司 阿尔茨海默病的治疗及预防方法
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (fr) 2021-05-24 2022-12-01 Eli Lilly And Company Anticorps anti-amyloïde bêta et leurs utilisations
WO2023283650A1 (fr) 2021-07-09 2023-01-12 Eisai R&D Management Co., Ltd. Biomarqueurs pour le traitement de la maladie d'alzheimer
CA3230148A1 (fr) 2021-08-30 2023-03-09 Eisai R&D Management Co., Ltd. Formulations sous-cutanees d'anticorps protofibrille anti-abeta et leurs methodes d'utilisation
TW202339794A (zh) 2022-02-02 2023-10-16 日商衛材R&D企管股份有限公司 使用ｐ—ｔａｕ１８１水平之治療方法
CN114578066B (zh) * 2022-05-07 2022-08-19 北京第一生物化学药业有限公司 检测β-淀粉样蛋白的产品和方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231000A (en) 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
US6174916B1 (en) 1990-04-27 2001-01-16 Milkhaus Laboratory, Ltd. Methods for treating herpes virus infections
EP0526511B1 (fr) 1990-04-27 1997-05-28 MCMICHAEL, John Procede et composition servant a traiter des etats pathologiques du systeme nerveux central associes a la proteine beta amyloide anormale
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
PT730643E (pt) 1993-10-27 2001-06-29 Lilly Co Eli Animais transgenicos portadores do alelo de app com mutacao sueca
EP0760676B1 (fr) 1994-05-25 2001-07-11 McMICHAEL, John Compositions et procedes de traitement de maladies a formation de plaque
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US6303567B1 (en) 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
JPH11514333A (ja) 1995-03-14 1999-12-07 プレーシス ファーマスーティカルズ インコーポレイテッド アミロイドの凝集の調節剤
US5854215A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
US5817626A (en) 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5985242A (en) 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
JPH09178743A (ja) 1995-12-27 1997-07-11 Oriental Yeast Co Ltd 可溶性ａｐｐの定量法
US6054114A (en) 1996-05-08 2000-04-25 Massachusetts Institute Of Technology Organometallic ligands for the localization and quantification of amyloid in vivo and in vitro
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US20030068316A1 (en) 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US20060178302A1 (en) 1997-02-05 2006-08-10 Northwestern University & The University Of Southern California Amyloid beta protein (globular assembly and uses thereof)
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
DE69831971T2 (de) 1997-12-03 2006-07-06 Neuralab Ltd., Flatts Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
AU2486900A (en) 1998-12-29 2000-07-31 University Of Georgia Research Foundation, Inc., The Rubredoxin fusion proteins, protein expression system and methods
WO2000071671A2 (fr) 1999-05-26 2000-11-30 New York University Nouveaux genes mutants dans la demence familiale britannique et la demence familiale danoise
PE20010212A1 (es) 1999-06-01 2001-02-22 Neuralab Ltd Composiciones del peptido a-beta y procesos para producir las mismas
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
WO2001006989A2 (fr) 1999-07-27 2001-02-01 Abgenix, Inc. Procedes et compositions permettant d'inhiber l'accumulation des polypeptides associee aux troubles neurologiques
JP4796725B2 (ja) 1999-08-04 2011-10-19 ユニバーシティ オブ サザン カリフォルニア アミロイドβタンパク質（球状アセンブリー及びその使用）
BR0016022A (pt) 1999-11-29 2002-08-06 Neurochem Inc Vacina para a prevenção e tratamento da doença de alzheimer e doenças relacionadas ao amilóide
DE60108111T2 (de) 2000-05-22 2005-12-08 New York University Synthetische immunogene jedoch nicht amyloidogene peptide, die homolog zu amyloid beta sind und deren verwendung zur induktion einer immunantwort gegen amyloid beta und amyloidaggregate
EP2082749A3 (fr) 2000-07-07 2010-06-30 Bioarctic Neuroscience AB Prévention et traitement de la maladie d'Alzheimer
US20030187011A1 (en) 2001-12-20 2003-10-02 Lashuel Hilal A. Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease
WO2003089460A1 (fr) 2002-04-19 2003-10-30 The Governing Council Of The University Of Toronto Methodes et compositions immunologiques pour le traitement de la maladie d'alzheimer
US20040049134A1 (en) 2002-07-02 2004-03-11 Tosaya Carol A. System and methods for treatment of alzheimer's and other deposition-related disorders of the brain
AU2003270643A1 (en) 2002-09-12 2004-04-30 The Regents Of The University Of California Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
EP1545582A4 (fr) 2002-10-01 2008-09-17 Univ Northwestern Ligands diffusibles derives de l'amyloide beta (addl), substituts d'addl, molecules de liaison aux addl, et leurs utilisations
JP2006505272A (ja) 2002-11-04 2006-02-16 バイオアークティック ニューロサイエンス アーベー βアミロイド前駆体タンパク質の構造およびプロセシングを調節する薬剤の同定のための方法
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20050124016A1 (en) 2003-08-01 2005-06-09 Enh Research Institute Antibodies specific for toxic amyloid beta protein oligomers
US20070003977A1 (en) 2003-08-20 2007-01-04 Amorfix Life Sciences Ltd Epitope protection assay and method for detecting protein conformations
EP1660533A4 (fr) 2003-09-12 2009-10-21 Univ California Anticorps monoclonaux specifiques a des intermediaires d'agregation de poids moleculaire eleve communs a des amyloides formes a partir de proteines de sequence differente
SE0400707D0 (sv) 2004-03-22 2004-03-22 Bioarctic Neuroscience Ab Transgenic animal model
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
AU2005269940A1 (en) 2004-07-02 2006-02-09 Northwestern University Monolocal antibodies that target pathological assemblies of amyloid beta (Abeta)
US20060079447A1 (en) * 2004-10-08 2006-04-13 Wetzel Ronald B Stabilized A-beta protofibrillar aggregates
US20080044356A1 (en) 2004-10-22 2008-02-21 Regents Of The University Of Minnesota Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof
EP2465872A3 (fr) 2004-10-25 2012-12-19 Merck Sharp & Dohme Corporation Anticorps anti-ADDL et leurs utilisations
US20060240486A1 (en) 2004-12-15 2006-10-26 Johnson-Wood Kelly L Immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies
AU2006211625A1 (en) 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US7731962B2 (en) 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
KR20080021585A (ko) 2005-03-05 2008-03-07 애보트 게엠베하 운트 콤파니 카게 스크리닝 방법, 비확산성 ａ-베타 올리고머의 정제 방법,당해 비확산성 ａ-베타 올리고머에 대한 선택적 항체 및당해 항체의 제조 방법
WO2006137354A1 (fr) 2005-06-21 2006-12-28 Medical & Biological Laboratories Co., Ltd. Anticorps avec effet inhibiteur sur la formation de fibrilles amyloïdes
TW200726482A (en) 2005-06-30 2007-07-16 Merck & Co Inc Method for preparing a covalently cross linked oligomer of amyloid beta peptides
TW200726774A (en) 2005-06-30 2007-07-16 Merck & Co Inc Composition and method for producing stable amyloid beta oligomers
RU2008120027A (ru) 2005-10-21 2009-11-27 Мерк энд Ко., Инк. (US) Анти-addl моноклональное антитело и его применение
CA2630964A1 (fr) 2005-11-22 2007-05-31 The Trustees Of The University Of Pennsylvania Traitement par anticorps de la maladie d'alzheimer et des maladies connexes
CA2630344C (fr) * 2006-03-23 2015-04-28 Bioarctic Neuroscience Ab Anticorps ameliores selectifs de protofibrilles et leur utilisation
UA100672C2 (en) * 2006-07-14 2013-01-25 Ас Иммуне Са HUMANIZED ANTIBODY TO b-AMYLOID PROTEIN
ME01758B (me) * 2006-07-14 2014-09-20 Genentech Inc Humanizirano protutijelo protiv amiloida beta
HUE033466T2 (en) * 2006-10-02 2017-12-28 Ac Immune Sa Humanized antibody to beta-amyloid
WO2009023185A1 (fr) * 2007-08-13 2009-02-19 Vasgene Therapeutics, Inc. Traitement contre le cancer utilisant des anticorps humanisés qui se lient à ephb4
EP3689912A1 (fr) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'un anticorps par point isoélectrique par substitution d'acide aminé dans cdr
NZ583632A (en) * 2007-11-16 2012-05-25 Univ Rockefeller Antibodies specific for the protofibril form of beta-amyloid protein
SI2282758T1 (sl) 2008-04-29 2019-03-29 Bioarctic Ab Protitelesa in vakcine za uporabo pri terapevtskih in diagnostičnih metodah za alfa-sinuklein-povezane motnje
SI3702371T1 (sl) 2009-03-25 2023-01-31 Genentech, Inc. Protitelesa proti FGFR3 in postopki za uporabo le-teh
US20120100129A1 (en) 2009-06-29 2012-04-26 Gellerfors Paer N-Terminal Truncated Protofibrils/Oligomers for Use in Therapeutic and Diagnostic Methods for Alzheimer's Disease and Related Disorders
CN102597233B (zh) * 2009-08-07 2014-10-29 协和发酵麒麟株式会社 人源化抗淀粉样-b寡聚体抗体
ES2661925T3 (es) * 2010-02-26 2018-04-04 Bioarctic Ab Anticuerpos de unión a las protofibrillas y su uso en métodos terapéuticos diagnósticos para la enfermedad de Parkinson, la demencia con cuerpos de Lewy y otras alfa-sinucleinopatías
CN103052649B (zh) * 2010-07-29 2015-12-16 Xencor公司 具有修改的等电点的抗体
PT2654790T (pt) 2010-12-22 2019-05-16 Teva Pharmaceuticals Australia Pty Ltd Anticorpo modificado com semivida melhorada

Also Published As

Publication number Publication date
AR101130A1 (es) 2016-11-23
JO3537B1 (ar) 2020-07-05
ZA201706272B (en) 2019-02-27
CL2017000053A1 (es) 2017-06-23
EP3865510A3 (fr) 2021-10-27
IL282823A (en) 2021-06-30
MA40224A (fr) 2017-05-17
DK3166970T3 (da) 2021-05-25
CN106661103A (zh) 2017-05-10
AU2015286707A1 (en) 2017-01-12
CN112390881A (zh) 2021-02-23
CO2017000346A2 (es) 2017-06-09
LT3166970T (lt) 2021-05-10
MA53887A (fr) 2021-10-27
ES2865112T3 (es) 2021-10-15
JP2017521427A (ja) 2017-08-03
BR112016030774A2 (pt) 2018-01-16
EP3166970B1 (fr) 2021-03-10
KR102564384B1 (ko) 2023-08-07
PL3166970T3 (pl) 2021-09-13
JP6628786B2 (ja) 2020-01-15
SI3166970T1 (sl) 2021-09-30
KR20170037900A (ko) 2017-04-05
CY1124563T1 (el) 2022-07-22
PE20170768A1 (es) 2017-07-04
RU2700104C2 (ru) 2019-09-12
SG11201610734RA (en) 2017-01-27
RU2017103446A (ru) 2018-08-13
PT3166970T (pt) 2021-04-26
IL282823B2 (en) 2024-05-01
WO2016005466A3 (fr) 2016-04-07
HUE053809T2 (hu) 2021-07-28
MX2017000378A (es) 2017-08-25
EP3865510A2 (fr) 2021-08-18
EP3166970A2 (fr) 2017-05-17
IL250001B (en) 2021-05-31
PH12017500032A1 (en) 2017-05-15
CA2951990C (fr) 2023-08-22
CA2951990A1 (fr) 2016-01-14
IL282823B1 (en) 2024-01-01
TWI678376B (zh) 2019-12-01
CN106661103B (zh) 2020-11-03
HRP20210680T1 (hr) 2021-06-11
AU2015286707A8 (en) 2017-01-19
TW201613964A (en) 2016-04-16
IL250001A0 (en) 2017-03-30
RU2017103446A3 (fr) 2019-02-26
WO2016005466A2 (fr) 2016-01-14
MY184890A (en) 2021-04-29
AU2015286707B2 (en) 2020-05-21
KR20230129449A (ko) 2023-09-08
RS61717B1 (sr) 2021-05-31
US20160009793A1 (en) 2016-01-14
US9573994B2 (en) 2017-02-21

Similar Documents

Publication Publication Date Title
MA40224B1 (fr) Anticorps se liant aux protofibrilles ass améliorés
MA41060A (fr) Compositions comprenant des souches bactériennes
MA55434A (fr) Compositions comprenant des souches bactériennes
MA41010A (fr) Compositions comprenant des souches bactériennes
MA40755B1 (fr) Compositions comprenant des souches bactériennes
MA40754B1 (fr) Compositions comprenant des souches bactériennes
MY164376A (en) Phosphospecific antibodies recognizing tau
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
MX356800B (es) Anticuerpo tau humanizado.
MY171300A (en) Pharmaceutical composition
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA44426B1 (fr) Compositions et méthodes pour diminier l'expression de tau
MA45172B1 (fr) Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
WO2015117088A3 (fr) Réactifs à base d'anticorps qui reconnaissent spécifiquement les formes de la protéine tdp-43 associées à une maladie neurodégénérative
MA38369B1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
EP4233901A3 (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
MX2021011596A (es) Compuestos y composiciones como moduladores de se?alizacion tlr.
MA39319A1 (fr) Inhibiteur de la protéine de transfert d'ester de cholestéryle (cetp) et compositions pharmaceutiques comprenant ledit inhibiteur pour leur utilisation dans le traitement ou la prévention de maladies cardiovasculaires
MA44660B1 (fr) (+) -azasetron pour son utilisation dans le traitement des troubles de l'oreille
EA202090961A1 (ru) Антитела к -синуклеину и их применения
MA35580B1 (fr) Composition pharmaceutique
MA42017B1 (fr) Anticorps anti-cd154 offrant des caractéristiques de liaison, fonctionnalité et sécurité améliorées et son utilisation dans l'immunothérapie humaine
EA201992245A1 (ru) Аналитические и терапевтические способы и композиции и их применение
MA41059B1 (fr) Compositions comprenant des souches bactériennes